Tillotts Pharma (Entocort) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 2

Tillotts Pharma (Entocort) General Information

Description

Global Rights for the drug Entocort. The drug is a 3 mg capsule used as a remedy for clinical remission of distal ulcerative colitis in the rectum, sigmoid and descending colon.

Contact Information

Formerly Known As
AstraZeneca (Entocort)
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Acquirer
Primary Office
  • The Sharp Building
  • Hogan Place
  • Dublin 2
  • Ireland
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Tillotts Pharma (Entocort) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Tillotts Pharma (Entocort)‘s full profile, request access.

Request a free trial

Tillotts Pharma (Entocort) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Tillotts Pharma (Entocort)‘s full profile, request access.

Request a free trial